Literature DB >> 22684223

Proximal colon cancers and the serrated pathway: a systematic analysis of precursor histology and BRAF mutation status.

Deepa T Patil1, Bonnie L Shadrach, Lisa A Rybicki, Brandie H Leach, Rish K Pai.   

Abstract

Although the serrated neoplasia pathway is thought to give rise to the majority of sporadic microsatellite instability-high (MSI-H) colon cancer, the exact proportion of these tumors that arise from serrated precursors has not been fully studied. Tubular and tubulovillous adenomas with features of the serrated neoplasia pathway have been described, and unlike sessile serrated adenomas, these lesions lack BRAF mutations. The contribution of these adenomas to sporadic MSI-H colon cancer is unclear. To this end, we conducted an analysis of right-sided sporadic MSI-H and microsatellite stable (MSS) colon cancer, with emphasis on precursor lesions. Overall 25% (19/75) of MSI-H colon cancer had a precursor, of which only 4 were recognized histologically as arising from a sessile serrated adenoma, and the remaining were best classified as adenomas. Of the 31 (of 89) MSS colon cancers with a precursor, only 1 was a sessile serrated adenoma (P=0.06). Histological analysis of the precursor adenomas to sporadic MSI-H colon cancer demonstrated a high frequency of crypt serrations compared with MSS colon cancer (93 vs 36%, P<0.001). BRAF mutations were found in 57/75 (76%) sporadic MSI-H and 10/89 (11%) MSS colon cancers (P<0.001). Molecular analysis demonstrated BRAF mutations in 11/12 adenoma and 3/3 sessile serrated adenoma precursors adjacent to BRAF-mutated MSI-H colon cancer. Similarly, all 4 precursors to BRAF-mutated MSS colon cancer were also BRAF mutated. The presence of BRAF mutations in these adenomatous precursors suggests that they represent sessile serrated adenomas with complete cytologic dysplasia. Finally, patients with sporadic MSI-H colon cancer were more likely to harbour synchronous sessile serrated adenomas (20 vs 8%; P=0.023). This is the largest study to rigorously evaluate the precursor and synchronous lesions in patients with right-sided colon cancer. Detailed molecular and histological analysis of these lesions confirms the importance of serrated precursors in the development of sporadic MSI-H colon cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22684223     DOI: 10.1038/modpathol.2012.98

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  19 in total

Review 1.  Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry.

Authors:  Jinru Shia; Susanne Holck; Giovanni Depetris; Joel K Greenson; David S Klimstra
Journal:  Fam Cancer       Date:  2013-06       Impact factor: 2.375

2.  Germline mutations in oncogene-induced senescence pathways are associated with multiple sessile serrated adenomas.

Authors:  Manish K Gala; Yusuke Mizukami; Long P Le; Kentaro Moriichi; Thomas Austin; Masayoshi Yamamoto; Gregory Y Lauwers; Nabeel Bardeesy; Daniel C Chung
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

3.  IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions.

Authors:  Takafumi Naito; Katsuhiko Nosho; Miki Ito; Hisayoshi Igarashi; Kei Mitsuhashi; Shinji Yoshii; Hironori Aoki; Masafumi Nomura; Yasutaka Sukawa; Eiichiro Yamamoto; Yasushi Adachi; Hiroaki Takahashi; Masao Hosokawa; Masahiro Fujita; Toshinao Takenouchi; Reo Maruyama; Hiromu Suzuki; Yoshifumi Baba; Kohzoh Imai; Hiroyuki Yamamoto; Shuji Ogino; Yasuhisa Shinomura
Journal:  World J Gastroenterol       Date:  2014-08-07       Impact factor: 5.742

4.  Distinct WNT/β-catenin signaling activation in the serrated neoplasia pathway and the adenoma-carcinoma sequence of the colorectum.

Authors:  Takashi Murakami; Hiroyuki Mitomi; Tsuyoshi Saito; Michiko Takahashi; Naoto Sakamoto; Naoshi Fukui; Takashi Yao; Sumio Watanabe
Journal:  Mod Pathol       Date:  2014-06-13       Impact factor: 7.842

5.  Usefulness of the Japan narrow-band imaging expert team classification system for the diagnosis of sessile serrated lesion with dysplasia/carcinoma.

Authors:  Takashi Murakami; Naoto Sakamoto; Hirofumi Fukushima; Tomoyoshi Shibuya; Takashi Yao; Akihito Nagahara
Journal:  Surg Endosc       Date:  2020-09-09       Impact factor: 4.584

6.  Distinct histopathological characteristics in colorectal submucosal invasive carcinoma arising in sessile serrated adenoma/polyp and conventional tubular adenoma.

Authors:  Takashi Murakami; Hiroyuki Mitomi; Takashi Yao; Tsuyoshi Saito; Tomoyoshi Shibuya; Naoto Sakamoto; Taro Osada; Sumio Watanabe
Journal:  Virchows Arch       Date:  2017-09-19       Impact factor: 4.064

7.  VE1 immunohistochemistry accurately detects BRAF V600E mutations in colorectal carcinoma and can be utilized in the detection of poorly differentiated colorectal serrated adenocarcinoma.

Authors:  Sara Sajanti; Päivi Sirniö; Juha P Väyrynen; Anne Tuomisto; Kai Klintrup; Jyrki Mäkelä; Ari Ristimäki; Markus J Mäkinen
Journal:  Virchows Arch       Date:  2014-04-11       Impact factor: 4.064

8.  Defined morphological criteria allow reliable diagnosis of colorectal serrated polyps and predict polyp genetics.

Authors:  Tilman T Rau; Abbas Agaimy; Anastasia Gehoff; Carol Geppert; Klaus Jung; Katharina Knobloch; Cord Langner; Alessandro Lugli; Irene Groenbus-Lurkin; Iris D Nagtegaal; Josef Rüschoff; Xavier Saegert; Mario Sarbia; Regine Schneider-Stock; Michael Vieth; Ellen C Zwarthoff; Arndt Hartmann
Journal:  Virchows Arch       Date:  2014-04-12       Impact factor: 4.064

Review 9.  Serrated neoplasia of the colon: what do we really know?

Authors:  Tanvir Haque; Kevin G Greene; Seth D Crockett
Journal:  Curr Gastroenterol Rep       Date:  2014-04

Review 10.  Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease.

Authors:  Shuji Ogino; Paul Lochhead; Andrew T Chan; Reiko Nishihara; Eunyoung Cho; Brian M Wolpin; Jeffrey A Meyerhardt; Alexander Meissner; Eva S Schernhammer; Charles S Fuchs; Edward Giovannucci
Journal:  Mod Pathol       Date:  2013-01-11       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.